Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Comparing Concurrent Chemoradiotherapy to Chemotherapy Alone for Locally Advanced Unresectable Pancreatic Cancer

절제 불가능한 췌장암의 동시 항암화학 방사선 요법과 항암화학 단독 요법의 비교

  • Park, Jeong-Hoon (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine) ;
  • Kim, Woo-Chul (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine) ;
  • Kim, Hun-Jung (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine) ;
  • Gwak, Hee-Keun (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine)
  • 박정훈 (인하대학교 의과대학 인하대학교병원 방사선종양학교실) ;
  • 김우철 (인하대학교 의과대학 인하대학교병원 방사선종양학교실) ;
  • 김헌정 (인하대학교 의과대학 인하대학교병원 방사선종양학교실) ;
  • 곽희근 (인하대학교 의과대학 인하대학교병원 방사선종양학교실)
  • Received : 2009.04.01
  • Accepted : 2009.05.28
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced unresectable pancreatic cancer. However, the introduction of gemcitabine and the recognition of a benefit in patients with advanced disease stimulated the design of trials that compare chemotherapy alone to concurrent chemoradiation. Therefore, we evaluated role of CCRT for locally advanced unresectable pancreatic cancer. Materials and Methods: We carried out a retrospective analysis of treatment results for patients with locally advanced unresectable pancreatic cancer between January 2000 and January 2008. The radiation was delivered to the primary tumor and regional lymph nodes with a 1~2 cm margin at a total dose of 36.0~59.4 Gy (median: 54 Gy). The chemotherapeutic agent delivered with the radiation was 5-FU (500 mg/$m^2$). The patients who underwent chemotherapy alone received gemcitabine (1,000 mg/$m^2$) alone or gemcitabine with 5-FU. The follow-up period ranged from 2 to 38 months. The survival and prognostic factors were analyzed using Kaplan-Meier method and log-rank test, respectively. Results: Thirty-four patients received concurrent chemoradiotherapy, whereas 21 patients received chemotherapy alone. The median survival time was 12 months for CCRT patients, compared to 11 months for chemotherapy alone patients (p=0.453). The median progression-free survival was 8 months for CCRT patients, compared to 5 months for chemotherapy alone patients (p=0.242). The overall response included 9 partial responses for CCRT and 1 partial response for chemotherapy alone. In total, 26% of patients from the CCRT group experienced grade 3~4 bowel toxicity. In contract, no grade 3~4 bowel toxicity was observed in the chemotherapy alone group. The significant prognostic factors of overall survival were lymph node status, high CA19-9, and tumor location. Conclusion: The response rate and progression-free survival were more favorable in the CCRT group, when compared with the chemotherapy alone group. Therefore, radiation therapy seems to be an effective tool for local tumor control.

목 적: 국소 진행되어 절제가 불가능한 췌장암에 있어 동시 항암화학 방사선 요법이 표준 요법으로 자리 잡아 왔다. 그러나 최근 들어 항암화학 단독 요법만으로도 좋은 결과를 보이는 연구 결과가 발표되고 있다. 이에 저자들은 국소 진행된 췌장암 환자들의 치료법에 따른 생존율 등을 비교하여 동시 항암화학 방사선 요법의 역할을 재조명하여 보고자하였다. 대상 및 방법: 2000년 1월부터 2008년 1월까지 인하대학교에서 절제 불가능한 췌장암으로 진단되어 치료를 받았던 55명의 환자를 대상으로 후향적 분석을 시행하였다. 동시 항암화학 방사선 요법은 5-FU에 기반한 항암화학 요법과 동시에 원발병소와 주위 림프절을 포함한 부분에 54 Gy (36~59.4 Gy)를 조사하였다. 항암화학 단독 요법은 gemcitabine단독 또는 5-FU와 병용하여 치료하였다. 치료 방법에 따른 치료반응과 전체 생존율 및 무진행생존율을 비교하였으며 예후인자들을 분석하였다. 결 과: 55명의 환자 중 동시 항암화학 방사선 요법을 받은 환자가 34명, 항암화학 단독 요법을 받은 환자가 21명이었다. 치료 방법에 따른 중앙 생존 기간은 각각 12개월, 11개월, 1년 생존율은 43%, 46%로 통계적으로 차이를 보이지 않았다. 중앙 무진행 생존기간은 각각 8개월, 5개월로 다소간 차이를 보였으나 통계적으로 의미있는 결과를 보이지는 않았다. 치료 반응도는 두 군 모두에서 완전 관해는 없었지만 부분 관해는 동시 항암화학 방사선 요법이 26%, 항암화학 단독 요법이 6%로 통계학적으로 의미 있는 차이를 보였다. 치료 중 독성은 동시 항암화학 방사선 요법이 장독성이 더 많았으나 다른 독성에는 차이가 없었다. 예후인자는 림프절 전이가 있는 경우, CA19-9이 1,000 U/ml 이상인 경우, 췌장암이 꼬리부분에 있는 경우가 나빴다. 결 론: 절제 불가능한 췌장암 치료에 있어서 동시 항암화학 방사선 요법이 항암화학 단독 요법에 비하여 무진행생존율을 향상 시키는 경향을 보였고, 치료 반응도에서도 더 좋은 결과를 보였다. 따라서 방사선 치료가 종양의 국소 제어에는 효과적인 것으로 생각된다.

Keywords

References

  1. Ministry of Health and Welfare, Republic of Korea. Annual report of the central cancer registry in Korea (2003. 1-2005. 12), 2008
  2. Perez CA, Brady LW. Principles and practice of radiation oncology. 5th ed. Philadelpia, PA; Lippincott Co., 2008:1343
  3. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867
  4. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710 https://doi.org/10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4
  5. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-755 https://doi.org/10.1093/jnci/80.10.751
  6. DeVita V, Hellman S, Rosenberg S. Cancer: principles and practice of oncology. 8th ed. Philadelphia, PA: Lippincott Co., 2008:1106-1107
  7. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD-SFRO study Ann Onc 2008;19:1592-1599 https://doi.org/10.1093/annonc/mdn281
  8. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378
  9. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001;7: 2246-2253
  10. Pipas JM, Mitchell SE, Barth RJ, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001;50:1317-1322 https://doi.org/10.1016/S0360-3016(01)01580-2
  11. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-4208 https://doi.org/10.1200/JCO.2001.19.22.4202
  12. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17:2208-2212 https://doi.org/10.1200/JCO.1999.17.7.2208
  13. Li C-P, Chao Y, Chi K-H, et al. Concurrent chemora-diotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Rad Oncol Biol Phys 2003;57:98-104 https://doi.org/10.1016/S0360-3016(03)00435-8
  14. Park JK, Ryu JK, Lee JK, et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006;33:397-402 https://doi.org/10.1097/01.mpa.0000236725.26672.be
  15. Bachet JB, Mitry E, Lepere C, et al. Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option? Gastroenterol Clin Biol 2007;31:151-156 https://doi.org/10.1016/S0399-8320(07)89347-X
  16. Ryu MR, Yoon SC, Kim YS, Chung SM. The results of palliative radiation therapy in patients with unresectable advanced pancreatic cancer. J Korean Soc Ther Radiol Oncol 2006;24:243-247
  17. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007;110:47-55 https://doi.org/10.1002/cncr.22735
  18. Koong AC, Christofferson E, Le Q-T, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005;63:320-323 https://doi.org/10.1016/j.ijrobp.2005.07.002

Cited by

  1. 절제 불가능한 국소 진행된 췌장암에서 방사선치료의 결과분석 vol.27, pp.3, 2009, https://doi.org/10.3857/jkstro.2009.27.3.145